-
公开(公告)号：US08779103B2
公开(公告)日：2014-07-15
申请号：US13256957
申请日：2010-03-24
申请人： Christopher Herring , Lucy J. Holt , Laurent S. Jespers , Sebastian Mayer , Malgorzata Pupecka-Swider
发明人： Christopher Herring , Lucy J. Holt , Laurent S. Jespers , Sebastian Mayer , Malgorzata Pupecka-Swider
IPC分类号： C12P21/08 , A61K39/395 , C07K16/46 , C07K14/575 , C12N15/62 , A61P3/00 , A61P3/04 , A61P3/08
CPC分类号： C07K14/605 , A61K38/26 , A61K39/3955 , A61K47/6803 , A61K47/6843 , C07K16/18 , C07K2317/21 , C07K2317/569
摘要： The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
摘要翻译： 本发明涉及具有改善的血清半衰期的药物融合物。 这些融合物和缀合物包含多肽，免疫球蛋白（抗体）单可变结构域和GLP和/或毒蜥外泌肽分子。 本发明还涉及包含这种药物融合物和缀合物的用途，制剂，组合物和装置。
-
2.发明申请LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR 审中-公开具有EGFR和/或VEGF结合特异性的配体及其使用方法公开(公告)号：US20100056439A1
公开(公告)日：2010-03-04
申请号：US12086020
申请日：2006-12-05
申请人： Roland Beckmann , Rudolf M T De Wildt , Steve Holmes , Olga Ignatovich , Laurent S Jespers , Haiqun Liu , Malgorzata Pupecka , Armin Sepp , Michael Steward
发明人： Roland Beckmann , Rudolf M T De Wildt , Steve Holmes , Olga Ignatovich , Laurent S Jespers , Haiqun Liu , Malgorzata Pupecka , Armin Sepp , Michael Steward
IPC分类号： A61K38/16 , C07K14/00 , C07K16/00 , C07K14/765 , C07H21/00 , C12N15/63 , C12N1/00 , C12P21/00 , A61P35/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/569
摘要： Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
摘要翻译： 公开了对血管内皮生长因子（VEGF），表皮生长因子受体（EGFR）或VEGF和EGFR具有结合特异性的配体。 还公开了使用这些配体的方法。 特别地，描述了这些配体用于癌症治疗的用途。
-
3.发明申请Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire 审中-公开从多肽汇编可逆地展开多肽的方法公开(公告)号：US20090005257A1
公开(公告)日：2009-01-01
申请号：US10556360
申请日：2004-05-14
CPC分类号： C40B40/02 , C07K1/1136 , C07K16/00 , C07K2317/567 , C07K2317/569 , C12N15/1037
摘要： The invention relates to polypeptides that unfold reversibly (e.g., unfolds when heated and refolds when cooled), to repertoires containing polypeptides that unfold reversibly and to libraries that contain polypeptides that unfold reversibly or nucleic acids that encode polypeptides that unfold reversibly. The invention further relates to processes for producing a library enriched in polypeptides that unfold reversibly or nucleic acids encoding polypeptides that unfold reversibly, processes for selecting and/or isolating polypeptides that unfold reversibly, and to methods for producing a polypeptide that unfolds reversibly.
摘要翻译： 本发明涉及可逆地展开的多肽（例如，当被冷却时被加热和重新折叠时展开），以及含有可逆展开的多肽的库和包含可逆展开的多肽的文库或编码可逆展开的多肽的核酸。 本发明还涉及产生富含可逆地展开的多肽的文库或编码可逆展开的多肽的核酸的方法，用于选择和/或分离可逆展开的多肽的方法，以及用于产生可逆展开的多肽的方法。
-
公开(公告)号：US20120100141A1
公开(公告)日：2012-04-26
申请号：US13256957
申请日：2010-03-24
CPC分类号： C07K14/605 , A61K38/26 , A61K39/3955 , A61K47/6803 , A61K47/6843 , C07K16/18 , C07K2317/21 , C07K2317/569
摘要： The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
摘要翻译： 本发明涉及具有改善的血清半衰期的药物融合物。 这些融合物和缀合物包含多肽，免疫球蛋白（抗体）单可变结构域和GLP和/或毒蜥外泌肽分子。 本发明还涉及包含这种药物融合物和缀合物的用途，制剂，组合物和装置。
-
5.发明申请Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY 审中-公开针对血清白蛋白和GLP-1或PYY的双特异性结构域抗体公开(公告)号：US20090214534A1
公开(公告)日：2009-08-27
申请号：US11791930
申请日：2005-11-30
CPC分类号： C12N15/62 , A61K38/00 , A61K39/3955 , A61K47/6811 , A61K47/6843 , C07K14/70578 , C07K14/7155 , C07K16/44 , C07K2317/569 , C07K2318/10 , C07K2318/20 , C07K2319/00 , C07K2319/31
摘要： Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
摘要翻译： 药物融合物和缀合物，其含有与结合血清白蛋白的抗体的抗原结合片段融合或缀合的肠促胰岛素治疗剂或诊断剂。 与非共轭或未融合的治疗或诊断剂相比，缀合物和融合物具有比体内较长的体内半衰期。
-
公开(公告)号：US20100247515A1
公开(公告)日：2010-09-30
申请号：US12663506
申请日：2008-06-04
申请人： Michael Steward , Malgorzata Pupecka , Ian Tomlinson , Carolyn Enever , Laurent S. Jespers , Thil Dinuk Batuwangala
发明人： Michael Steward , Malgorzata Pupecka , Ian Tomlinson , Carolyn Enever , Laurent S. Jespers , Thil Dinuk Batuwangala
IPC分类号： A61K39/395 , C07K16/18 , A61P35/00 , A61P1/00 , A61P1/06
CPC分类号： C07K16/005 , A61K9/0078 , A61K2039/544 , C07K16/22 , C07K16/2866 , C07K16/2878 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.025 秒)
